Evaluation of Topical Wound Oxygen (two2) Therapy

Diabetic Ulcer Clinical Trial

Official title:

A Randomized, Double-blinded, Parallel Group, Placebo-Controlled, Multi-Center Trial of Topical Wound Oxygen Therapy in the Treatment of Diabetic Lower Extremity Ulcers

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00871312
• Other study ID #: AOTI-001
• Status: Terminated
• Phase: N/A
• First received: March 26, 2009
• Last updated: January 8, 2014
• Start date: May 2007
• Est. completion date: December 2009

Study information

• Verified date: January 2014
• Source: AOTI Ltd.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of the Topical Wound Oxygen (two2) therapy system on the healing of diabetic lower extremity ulcers.

Description:

The AOTI two2 therapy trial is a randomized, double-blinded, parallel group, placebo-controlled, multi-center study intended to evaluate the efficacy of Topical Wound Oxygen (two2) therapy in relation to placebo when added to standard of care in the treatment of diabetic lower extremity ulcers.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 21
• Est. completion date: December 2009
• Est. primary completion date: December 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject or legal representative has read, understands, and has signed the Institutional Review Board (IRB)-approved Informed COnsent Form (ICF) prior to enrollment in the study;

• Subject is 18 years of age or older;

• Subject has a current diagnosis of Type I or Type II diabetes mellitus;

• Subject has a diabetic lower extremity ulcer;

• Subject's index ulcer is at least 1.0cm2 in area;

• Subject's index ulcer is a superficial, partial or full thickness skin ulcer (Wagner Classification System I, II or III) which has been present for at least 4 weeks at the time of initial screening that has not improved with standard of care;

• Subject's index ulcer appears to be free of sinus tracts and tunneling;

• Subject's index ulcer exhibits no signs of moderate or severe clinical infection;

• In the event of multiple wounds on the same foot, the index ulcer will be the largest ulcer meeting the other inclusion criteria;

• In the event of multiple wounds on the same foor, the index ulcer is at least 2 cm from any additional wound edge;

• Women of childbearing potential must not be pregnant or lactating;

• Subject and/or caregiver are willing and able to comply with all specified care and visit requirements, and subject has a reasonable expectation of completing the study;

• Subject must be fit to undertake the study trial in the opinion of the referring doctor

• Subject's Great Toe pressure is greater than 20mmHg.

Exclusion Criteria:

• Subject is currently enrolled in another investigational device or drug trial, or has been previously enrolled in investigative research for a device or pharmaceutical agent within the last 30 days;

• Subject's index ulcer has gangrene or gangrene is located on any part of the foot with the index ulcer;

• Subject has an acute and/or active Deep Vein Thrombosis;

• Subject is currently receiving or has received in the last six (6) months radiation or chemotherapy;

• Subject has received growth factor therapy within seven (7) days prior to initial screening;

• Subject has a significant medical condition that would impair wound healing, for example: severe liver disease, aplastic anemia, scleroderma, malnutrition, malignancy, etc;

• Subject has known or suspected osteomyelitis;

• Other than debridement, the underlying wound pathology requires surgical correction for the index ulcer to heal;

• Subject is receiving or has received corticosteroids (all applications), immunosuppressive agents, or other drugs that would impair wound healing within seven (7) days prior to initial screening or is anticipated to require them during the course of the study;

• Subject has an acute or active Charcot foot per clinical and radiology results or significant bony prominences that would preclude adequate off-loading with the standard off-loading device. The presence of Charcot foot in itself does not exclude the subject;

• Subject has known HIV, hepatitis, active cancer (except basal cell and non-melanoma skin cancer), or a bleeding disorder;

• Subject is undergoing renal dialysis;

• Subject suffers from known alcohol or drug abuse;

• Use of the standard off-loading device is contra-indicated or cannot be appropriately fitted to the subject.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetic Ulcer

Intervention

Device:
• Topical wound oxygen therapy
90 minutes 4 days per week Active Topical Oxygen Therapy
• Topical wound oxygen Placebo
90 mins per day 4 days per week Placebo Therapy

Locations

Country	Name	City	State
Canada	Community Dermatology & Wound Healing Clinic	Mississauga	Ontario
Canada	Wound Care Clinic	St. Catherines	Ontario
United States	AOTI Clinic	Buffalo	New York

Sponsors (1)

Lead Sponsor	Collaborator
AOTI Ltd.

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Wound closure		12 Weeks	No
Secondary	The time to wound closure		Variable	No
Secondary	The degree of wound closure		4, 8, and 12 weeks	No
Secondary	The percentage of tissue types		4, 8 and 12 weeks	No
Secondary	The type and amount of wound drainage or exudates		4, 8 and 12 weeks	No
Secondary	The level of wound pain		4, 8 and 12 weeks	No